trending Market Intelligence /marketintelligence/en/news-insights/trending/ehdDk3ewzCqOpFGWKbLxhQ2 content esgSubNav
In This List

US FDA accepts for review Supernus' application for ADHD drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA accepts for review Supernus' application for ADHD drug

The U.S. Food and Drug Administration accepted for review Supernus Pharmaceuticals Inc.'s application for attention deficit hyperactivity disorder drug SPN-812.

The drug is intended for the treatment of children and adolescents with ADHD. Symptoms of the disorder include difficulty paying attention, being overactive and acting impulsively.

The regulator is expected to make a decision by Nov. 8.

Rockville, Md.-based Supernus' new drug application is backed by data from four phase 3 clinical studies, two mid-stage ones and several phase 1 trials. Results from the studies showed the medication reduced ADHD symptoms such as hyperactivity, impulsive behavior and inattention in children.

The company started another phase 3 trial of SPN-812 in adult ADHD patients in late 2019.

Supernus Pharmaceuticals develops and commercializes products to treat central nervous system diseases in the U.S.